ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,064.20
      0.91%
      US Tech 100
      17,173.20
      1.85%
      Dow Jones
      38,225.66
      0.85%
      Brent Oil
      83.875
      0.29%
      Bitcoin
      59,411.95
      0.49%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Cullinan Therapeutics Inc (CGEM)

      7. Cullinan Therapeutics Inc (CGEM) News

      CGEM

      Cullinan Therapeutics (CGEM)

      Cullinan Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CGEM
      DateTimeSourceHeadlineSymbolCompany
      2:07PMiHub NewswireFeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
      04/29/20247:00AMGlobeNewswire Inc.Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerNASDAQ:CGEMCullinan Therapeutics Inc
      04/24/202410:09AMGlobeNewswire Inc.Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
      04/16/20247:00AMGlobeNewswire Inc.Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesNASDAQ:CGEMCullinan Therapeutics Inc
      04/16/20246:59AMGlobeNewswire Inc.Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementNASDAQ:CGEMCullinan Therapeutics Inc
      03/14/20247:00AMGlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
      03/01/20247:00AMGlobeNewswire Inc.Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple MyelomaNASDAQ:CGEMCullinan Therapeutics Inc
      02/27/20248:00AMGlobeNewswire Inc.Cullinan Oncology to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
      02/23/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      02/23/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      02/23/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      02/14/20249:01PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CGEMCullinan Therapeutics Inc
      02/02/20249:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      02/01/20244:43PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      01/30/20247:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      01/29/20244:27PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      01/24/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      01/22/20244:18PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      01/08/20244:15PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
      01/08/20249:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
      12/22/20235:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      12/22/20235:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      12/22/20235:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      12/22/20235:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      12/20/20236:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      12/20/20236:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      12/20/20236:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      12/20/20236:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
      12/18/20234:53PMGlobeNewswire Inc.Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
      12/14/20234:30PMGlobeNewswire Inc.Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesNASDAQ:CGEMCullinan Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:CGEM